Introduction
There is great concern amongst ecologists and the general public over the loss of species particularly in the animal kingdom. For the past 30 or more years we have seen a similar phenomenon in pharmacological science -the loss of important compounds that are vital to research particularly in the clinical field. It is now time to acknowledge the scale and significance of this problem. In an effort to remedy this problem, the ECNP are trying to facilitate access for researchers to pharmacological tools in order to support experimental medicine studies through the Medicines Chest initiative. Targeted compounds for inclusion in the Medicines Chest are those that have selective actions at important brain targets, and could readily be employed in human studies, for example, compounds that have been shelved by Pharmaceutical companies but for which clinical safety packages and possibly active pharmaceutical ingredients are available.
The drug discovery and disappearance process
Most drug discovery and clinical development is done by the pharmaceutical industry. This is for reasons of time and cost. It takes over a decade and up to a billion dollars to get a drug on the market, and few non-commercial or charity funders have access to this level of resource. At many points in this process "failure" can occur and the drug is then shelved, often with no further exploration of other possible therapeutic indications. Such drugs then disappear from the company's consciousness, and then from the archives, so that they may never be seen or heard of again. This loss of access to useful research tools and the accrued knowledge is vast and spreads across all areas of drug discovery and development. This is a contributory reason to why so many new drugs fail to make the transition to successful clinical treatments. Preclinical pharmacology models readily deliver new targets for drug discovery, but the translation to human psychiatric illness is poor. A major reason for this is that tool compounds are not available for human research.
Although the published data on the compound is in the public domain, a lot of important data covering the safety profile and manufacturing is never published. Moreover although some compounds are made available to preclinical researchers via chemical supply companies, clinical research is almost invariably impossible so a whole clinical research field can suddenly terminate. Following are two examples from brain research, the area of interest to the ECNP Medicines Chest initiative, though similar issues can be found in other treatment areas.
Noradrenaline is a long-established brain neurotransmitter that animal studies indicate is involved in the regulation of attention and arousal and may be abnormal in conditions such as depression, drug addiction and dementias (Brunello et al., 2002; Sofuoglu and Sewell, 2009; Herrmann et al., 2004) . Brain noradrenaline works through several subtypes of receptors -the alphas [1,2] and the betas [1, 2, 3] . In order to fully understand this system in human brain function and disease it is necessary to have access to drugs that selectively target each receptor subtype. In the 1980s several companies developed compounds that acted as antagonists of the α2 receptor because blocking this receptor takes off the pre-synaptic break on noradrenaline release, thus enhancing its actions. These drugs were developed as possible treatments for depression, some forms of dementia, diabetes, and as add-on treatments for Parkinson's disease and schizophrenia (Nutt and Pinder, 1996) . A number of very selective molecules were made and several were taken into human studies where clear evidence of predicted pharmacological actions was found, e.g. in sustaining attention (Coupland et al., 1994) . Now none are available for human study. Recently, as part of the ECNP Medicines Chest initiative, we contacted GlaxoSmithKline (GSK) in order to try to locate fluparoxan, arguably the best of these compounds. This was made in Glaxo in the 1980s and has been used in humans (Johnson et al., 1995) . Despite the best efforts of senior members of the company the records for fluparoxan could not now be located in GSK. The drug for all practical purposes is extinct. Currently we have managed to make available another old α2 adrenoceptor compound, idazoxan, in the Chest. This has a good safety record in human studies Open access under CC BY-NC-ND license.
psychoactive as it affects sleep profiles . However idazoxan is not as selective as the compounds mentioned above as it also binds to the imidazoline I 2 receptor.
You may say why not just make some more. That is of course possible for preclinical research, though it would be relatively expensive for a single researcher. However for human studies under the Europe clinical trials directive this would not suffice. In order to give this drug to patients, details of the exact drug substance and drug product preparation used for the original compound are required. Without this information from the company any researcher would need to develop their own synthetic process, and then re-do the animal and human toxicity testing before being able to use the drug for research. This would cost £k1000 or more, clearly outside any grant giving bodies' budget. Moreover it is a waste of resource and animals.
Another example is that of the GABA A α5 subtype receptor inverse agonist, α5IA, a compound made by Merck Sharp & Dohme (MSD). This is the first such compound to have been shown to have the predicted pro-memory effects in humans (Atack, 2010) . Moreover in a mouse model of Down's Syndrome, it normalised the memory deficits in several tasks (Braudeau et al., 2011) . It was dropped by MSD because it did not have a good enough memory enhancing signal in studies of elderly volunteers with agerelated memory impairment. However when we tried to get the information necessary to re-synthesise it for a proof-ofconcept trial in human patients with Down's Syndrome the company was unable to make the necessary data available and the costs of re-doing the full dossier were too large to go for it alone.
The scale of the problem
The true extent of this loss of knowledge and compounds is hard to ascertain as there is no systematic capture of this kind of data. The ECNP has for some years been concerned about it (Nutt and Goodwin, 2011) and approached the issue from the perspective of its members through the Medicines Chest initiative. We sent out a questionnaire to all our members asking for compounds that they would like to study but could not access. Over 50 were identified and then those with the most requests were prioritised for further exploration. Companies were approached to see if these compounds had been discontinued or sold on, and in the latter case we followed up with the new company. From this process several important tool compounds with plausible availability were identified -see Table 1 . These cover a range of biologically important receptors for which there are in most cases no available alternatives.
How drugs disappear
It seems paradoxical that when so much is invested in developing a compound it is allowed to die. Is it not a resource on which further research can be done, leading to new insights that can only be tested by the drug?
The reasons why drugs become extinct after failing in clinical trials, or at least not made available for other research, derive from a complex mixture of commercial and emotional decisions. Historically there might have been active attempts to suppress knowledge of the "failure" of a drug although this is becoming less of an issue now that increasingly governments and regulators are requiring disclosure of all data from Phase 2 and Phase 3 trials, irrespective of outcome. Additionally, some pharmaceutical companies are run by individuals who may not see the value of drug assets to the academic world.
There are also the costs involved in maintaining supplies of the compounds for research. They need to be tested for stability and purity on a regular basis and at some point re-synthesised. Any subsequent work in patients will also require some form of monitoring of adverse effects which requires a data-base and someone to run it. All these have tangible costs, which may deter companies. However, the expenditures could be made more efficient if a number of groups are pulled together to work on one compound. An intangible cost is the threat of litigation, particularly in the US courts, should some harm come to a subject given the drug. Although this is tenuous -why would a subject in say a European study with local insurance sue the originating US company? Some company lawyers will argue that there is a minute chance of this happening, so it is better to play safe. Such risk aversion tends to trump any pro-science arguments that can be put forward. That said, most companies with which we have discussed the Medicines Chest do not see this as a major issue. 
How the Medicines Chest works
The key to the success of this initiative is to make available to bona fide researchers with the necessary skills to properly use them as many of these compounds as possible, and to add more to the chest as time, money and compound availability permits. Targeted compounds for inclusion in the Medicines Chest are those that have selective actions at important brain targets which are currently inaccessible to academic researchers for human studies. Such compounds will have safety packages supporting use in humans. Preferably active pharmaceutical ingredient will also be available but if not, new material will need to be synthesised, the cost of which will need to be met by funding bodies.
The ECNP Medicines Chest serves as a guardian of data for compounds, maintains live Investigator's Brochures (and other regulatory documentation) and where possible usable drug substance and drug product. After agreement in principle that a compound is available to the medicines chest, a template agreement is established with the company. This or something very similar is then used for each study, which are funded by grant-giving bodies. The ECNP reviews study proposals to ensure that only those of a high quality reach the company concerned. Data generated from studies with compounds in the medicines chest is made publically available.
Gaboxadol -a successful example
Gaboxadol is already in the Chest. This is a Lundbeck compound that was made to mimic the effects of the natural inhibitory neurotransmitter GABA. As GABA is involved in sleep regulation it was tested as a sleep promoting drug where efficacy was found but for various reasons it was not taken to market. The neuroscience of GABA receptors has evolved significantly in the period gaboxadol was under development and it now appears that this drug is an extra-synaptic GABA A agonist working at a specific subtype of this receptor class (Meera et al., 2011) . Gaboxadol is the only such compound currently known and available for human work and so it is a critical tool for exploring the role of these receptors in human brain function. Through the Medicines Chest Lundbeck made it possible to conduct a magnetoencephalography (MEG) study with gaboxadol and compare it with other classes of drugs that enhance GABA A function such as the intra-synaptic agonist zolpidem and the GABA reuptake blocker tiagabine. These results were remarkable as they, against all expectations, showed very different resting MEG profiles for the three drugs, despite similar psychological effects. These findings now need to be "back-translated" into preclinical models of the role of GABA in cortical functioning. Table 2 below shows the current status of the ECNP Medicines Chest. Three compounds are in the chest and discussions are ongoing for the "probables"; we hope to have some of these in the chest in the next year.
The current status of the Medicines Chest

Conclusions
Clinical neuroscience lags behind its preclinical relative in many ways, an important one being the lack of pharmacological tools to study brain function. Many of these tool compounds have been developed but almost none are available for human research. This situation is a serious indictment of the current scientific process. Yet it is one that should be avoidable given a willingness of the pharmaceutical industry to make their assets available to researchers and the provision of a mechanism for curating data and even test substances on the drugs in question. The UK Medical Research Council (MRC) and the Stanley Foundation have said that they will be pleased to review grant proposals based on drugs from the Medicines Chest, so what is now needed is a collective effort to make it happen. The scale and cost of the initiative are too great for a single organisation like ECNP to take on alone, though they are happy to act as curators of the Medicines Chest. Possible other sources of support include the new European Community science initiative Horizons 2020 and the Innovative Medicines Initiative (IMI) within it. Maybe the US and European human brain projects will also consider supporting it? 
